A clinical trial referencing MOTS-c was registered, with an update logged on June 11, 2026. The study is titled "Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding" and is listed under identifier NCT07638696.
The trial's current status is not yet recruiting. No phase designation was provided for this study. MOTS-c is classified as unapproved and remains in the research stage, without any approved therapeutic use.
According to the listing, the trial aims to explore mitophagy and mitochondrial DNA dynamics under two dietary conditions: Ramadan dry fasting and 16:8 time-restricted feeding. No outcomes, results, or efficacy data have been posted at this time, as the study has not yet begun recruiting participants.
Further details on trial design, eligibility, and timeline may become available as the study progresses toward recruitment. Readers are encouraged to consult the official registry listing for the most current status updates on this trial.
For more background on this compound, readers can refer to the MOTS-c overview.